Analyst Ratings For Collegium Pharmaceutical Inc (NASDAQ:COLL)
Today, Cantor Fitzgerald set its price target on Collegium Pharmaceutical Inc (NASDAQ:COLL) to $35.00 per share.
There are 7 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on Collegium Pharmaceutical Inc (NASDAQ:COLL) is Buy with a consensus target price of $32.6667 per share, a potential 72.11% upside.
Some recent analyst ratings include
- 9/17/2018-Collegium Pharmaceutical Inc (NASDAQ:COLL) had its Buy rating reiterated by HC Wainwright
- 3/8/2018-Collegium Pharmaceutical Inc (NASDAQ:COLL) had its Outperform rating reiterated by William Blair
- On 11/15/2018 Michael Thomas Heffernan, Director, sold 25,000 with an average share price of $16.60 per share and the total transaction amounting to $415,000.00.
- On 10/15/2018 Michael Thomas Heffernan, Director, sold 25,000 with an average share price of $16.53 per share and the total transaction amounting to $413,250.00.
- On 6/21/2018 Paul Brannelly, Insider, sold 10,000 with an average share price of $27.92 per share and the total transaction amounting to $279,200.00.
- On 6/12/2018 Alison B Fleming, Insider, sold 4,096 with an average share price of $27.00 per share and the total transaction amounting to $110,592.00.
- On 6/12/2018 Michael Thomas Heffernan, Chairman, sold 150,000 with an average share price of $25.27 per share and the total transaction amounting to $3,790,500.00.
- On 6/1/2018 Joseph Ciaffoni, COO, sold 79,683 with an average share price of $22.59 per share and the total transaction amounting to $1,800,038.97.
- On 4/19/2018 Michael Thomas Heffernan, Chairman, sold 44,400 with an average share price of $26.00 per share and the total transaction amounting to $1,154,400.00.
About Collegium Pharmaceutical Inc (NASDAQ:COLL)
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving. The company offers Xtampza, an abuse-deterrent, extended-release, oral formulation of oxycodone for opioid medication. It is also developing Onsolis, a transmucosal immediate-release fentanyl film indicated for the management of breakthrough pain in cancer patients 18 years of age and older. In addition, the company offers Nucynta ER, an extended release formulation of tapentadol for the management of pain severe enough to require daily, around-the-clock, long term opioid treatment, such as neuropathic pain related to diabetic peripheral neuropathy in adults; and Nucynta IR, an immediate release formulation of tapentadol that is indicated for the management of moderate to severe acute pain in adults. Further, it is developing COL-195, an abuse-deterrent, extended-release hydrocodone for the treatment of chronic pain; COL-172, an abuse-deterrent, extended-release oxymorphone for the treatment of chronic pain; and COL-171, a proprietary preclinical DETERx extended-release, abuse-deterrent methylphenidate formulation for attention deficit hyperactivity disorder (ADHD), as well as COL-196, a morphine formulation. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Recent Trading Activity for Collegium Pharmaceutical Inc (NASDAQ:COLL)
Shares of Collegium Pharmaceutical Inc closed the previous trading session at 18.98 −0.49 2.52% with 19.44 shares trading hands.
